On February 11, 2021 Starpharma (ASX: SPL,OTCQX: SPHRY) reported that is has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth NJ USA (Press release, Starpharma, FEB 11, 2021, View Source [SID1234574959]). Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP technology .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr Jackie Fairley, CEO of Starpharma commented: "MSD is a recognised leader in oncology, and we are delighted to have signed this new Research Agreement in such an innovative and valuable area."

DEP ADCs exploit the unique potential of Starpharma’s DEP technology to provide enhanced characteristics to ADCs including greater homogeneity, site specific attachment, and higher drug antibody ratio (DAR), than conventional ADC approaches. DEP ADCs are the subject of internal and partnered programs.

Starpharma has previously demonstrated the significant advantages conveyed by DEP ADCs in multiple preclinical studies, including its DEP HER-2 ADC, which showed significant tumour regression and 100% survival, outperforming Herceptin & Kadcyla in a human ovarian cancer model. Starpharma’s DEP technology has already yielded four clinical stage oncology products, including one under development by AstraZeneca.